Abstract:Isocitrate dehydrogenase (IDH) inhibitors are transforming the treatment of patients with non-enhancing grade 2 IDH-mutant gliomas. Uncertainty remains on the utility of IDH-inhibitors in high-grade IDH-mutant glioma patients that had prior therapies and have progressive disease. From October 2020 to December 2023, we identified high-grade IDH1-mutant patients treated with off-label ivosidenib, a mutant IDH1 inhibitor. We report their clinical and imaging characteristics. In our cohort (n=18), the patient age range was 29-68 years with male predominance (n=11). Diagnoses included astrocytoma grades 3 (n=9) or 4 (n=2), and oligodendroglioma grade 3 (n=7). The median number of progressions prior to ivosidenib initiation was 2 (range 1-7). Fifteen patients had prior surgical resection, three had biopsy. Prior treatment exposures included radiation therapy (n=15), temozolomide (n=18), lomustine (n=5), bevacizumab (n=3), etoposide (n=1), optune (n=1) and a clinical trial (n=1). Mean time from diagnosis to ivosidenib treatment was 9.6 years (95% CI, 6.7 to 16.4 years). Karnofsky performance-status score upon initiation was 80 (n=6) or 90 (n=12). Thirteen patients had >1 cm enhancing disease, five had non-enhancing disease. Ivosidenib was initiated due to enhancing disease progression (n=11), non-enhancing disease progression (n=4), a combination of both (n=2) or temozolomide intolerance (n=1). Best radiographic responses per RANO criteria were partial response (n=2), minor response (n=3), stable disease (n=7), and progressive disease (n=6). Nine patients continue ivosidenib without disease progression, with a median treatment duration of 27.5 months (95% CI, 18.0 to 33.0 months). All had FLAIR stabilization/improvement and 45% (n=4) had improved enhancing disease. Nine patients discontinued ivosidenib due to progression, with a median treatment duration of 7 months (95% CI, 3 to 9 months). These data suggest that treatment with an IDH inhibitor can provide disease control for some high-grade IDH-mutant glioma patients who had prior therapies and progressive disease. Future studies are needed to investigate this patients population.

Vorasidenib: a new hope or a false promise for patients with low-grade glioma?

A Promising Breakthrough: The Potential of VORASIDENIB in the Treatment of Low-grade Glioma

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Vorasidenib: First Approval

The Role of Mutant IDH Inhibitors in the Treatment of Glioma

Ctni-53. A Global, Randomized, Double-Blinded, Phase 3 Study Of Vorasidenib Versus Placebo In Patients With Adult-Type Diffuse Glioma With An Idh1/2 Mutation (Indigo): Updated Efficacy Results

Vorasidenib and Ivosidenib in IDH1-mutant Low-Grade Glioma: a Randomized, Perioperative Phase 1 Trial.

IDH inhibition in gliomas: from preclinical models to clinical trials

Advances in the treatment of IDH-mutant gliomas

Treatment of IDH-mutant glioma in the INDIGO era

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside

Innv-37. Real-World Outcomes Among High Grade Idh1-Mutant Glioma Patients Treated With An Idh Inhibitor

Advances in gene therapy for high-grade glioma: a review of the clinical evidence

Innv-31. The Use Of Ivosidenib In Patients With Enhancing Idh1 Mutant Gliomas

Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma

Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment

Exth-08. Ivosidenib Therapy For Idh-Mutant Who Grade 4 Astrocytoma

How will tovorafenib change our treatment of pediatric low-grade glioma?

Capitalizing on Hope: Questionable Marketing Approval and Pricing of a New ALS Drug

Innv-07. Ivosidenib And Bevacizumab In Heavily Pretreated Patients With Idh1 Mutant Gliomas